Total Payments
$1.1M
2024 Payments
$33,204
Companies
29
Transactions
506
Payment Breakdown by Category
Consulting$947,176 (82.9%)
Other$105,834 (9.3%)
Travel$54,358 (4.8%)
Research$29,490 (2.6%)
Food & Beverage$5,377 (0.5%)
Education$582.49 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $947,176 | 203 | 82.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $81,209 | 35 | 7.1% |
| Travel and Lodging | $54,358 | 80 | 4.8% |
| Unspecified | $29,490 | 40 | 2.6% |
| Honoraria | $24,625 | 8 | 2.2% |
| Food and Beverage | $5,377 | 137 | 0.5% |
| Education | $582.49 | 3 | 0.1% |
Payments by Type
General
$1.1M
466 transactions
Research
$29,490
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $728,123 | 146 | $0 (2024) |
| Janssen Research & Development, LLC | $155,034 | 39 | $0 (2024) |
| Genentech USA, Inc. | $48,505 | 50 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $48,306 | 58 | $0 (2024) |
| Eli Lilly and Company | $45,272 | 42 | $0 (2022) |
| GlaxoSmithKline, LLC. | $23,037 | 29 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $23,022 | 40 | $0 (2024) |
| Novartis Pharma AG | $22,099 | 6 | $0 (2022) |
| EMD Serono, Inc. | $13,073 | 7 | $0 (2022) |
| Roche Products Limited | $6,920 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33,204 | 30 | PFIZER INC. ($10,970) |
| 2023 | $33,467 | 38 | Janssen Research & Development, LLC ($18,135) |
| 2022 | $188,535 | 40 | PFIZER INC. ($109,432) |
| 2021 | $113,145 | 34 | Janssen Research & Development, LLC ($65,700) |
| 2020 | $55,241 | 44 | PFIZER INC. ($28,190) |
| 2019 | $110,487 | 110 | PFIZER INC. ($50,045) |
| 2018 | $443,297 | 103 | PFIZER INC. ($373,459) |
| 2017 | $165,442 | 107 | PFIZER INC. ($122,755) |
All Payment Transactions
506 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,820.00 | General |
| 11/26/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: XELJANZ CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,820.00 | General |
| 10/25/2024 | UCB SA | Cimzia (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Immunology | ||||||
| 10/25/2024 | UCB SA | Cimzia (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 10/16/2024 | Janssen Research & Development, LLC | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $2,170.00 | General |
| Category: Immunology | ||||||
| 10/16/2024 | Janssen Research & Development, LLC | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $310.00 | General |
| Category: Immunology | ||||||
| 10/16/2024 | Janssen Research & Development, LLC | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $310.00 | General |
| Category: Immunology | ||||||
| 10/04/2024 | ABBVIE INC. | RINVOQ (Biological), HUMIRA | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: XELJANZ CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/27/2024 | UCB SA | Cimzia (Drug) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: Immunology | ||||||
| 09/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $123.96 | General |
| Category: IMMUNOLOGY | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | ILARIS (Drug) | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: Immunology | ||||||
| 08/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.41 | General |
| Category: IMMUNOLOGY | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | ILARIS (Drug) | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: Immunology | ||||||
| 08/08/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/08/2024 | ABBVIE INC. | HUMIRA (Biological), RINVOQ | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: IMMUNOLOGY | ||||||
| 06/20/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: Inflammation | ||||||
| 05/30/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/06/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/02/2024 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/03/2024 | Janssen Research & Development, LLC | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $2,170.00 | General |
| Category: Immunology | ||||||
| 04/03/2024 | Janssen Research & Development, LLC | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $310.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $21,820 | 17 |
| CAIN457F2304 | Novartis Pharmaceuticals Corporation | $1,744 | 1 |
| A 24 WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL TRIAL WITH A 16 WEEK OPEN-LABEL LEAD-IN PHASE, AND 64 WEEK OPEN-LABEL FOLLOW-UP, TO EVALUATE THE EFFECT ON CLINICAL RESPONSE AND THE SAFETY OF TOCILIZUMAB IN PATIENTS WITH ACTIVE POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS. | F. Hoffmann-La Roche AG | $1,306 | 1 |
| A PHASE IB, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS | F. Hoffmann-La Roche AG | $1,280 | 8 |
| XELJANZ CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| A PHASE IB, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS, A PHASE IB, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS | F. Hoffmann-La Roche AG | $620.10 | 2 |
| LONG-TERM, INTERVERNTIONAL, OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY OF TOCILIZUMAB TREATMENT IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS WHO COMPLETED THE GLOBAL, MULTINATIONAL TRIAL WA19977, A 24 WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL TRIAL WITH A 16 WEEK OPEN-LABEL LEAD-IN PHASE, AND 64 WEEK OPEN-LABEL FOLLOW-UP, TO EVALUATE THE EFFECT ON CLINICAL RESPONSE AND THE SAFETY OF TOCILIZUMAB IN PATIENTS WITH ACTIVE POLYARTICULAR-COURSE JUVENIL | F. Hoffmann-La Roche AG | $579.55 | 1 |
| A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF TOCILIZUMAB ON DISEASE RESPONSE IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, WITH AN OPEN-LABEL EXTENSION TO EXAMINE THE LONG TERM USE OF TOCILIZUMAB | F. Hoffmann-La Roche AG | $533.44 | 5 |
| A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF TOCILIZUMAB ON DISEASE RESPONSE IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, WITH AN OPEN-LABEL EXTENSION TO EXAMINE THE LONG TERM USE OF TOCILIZUMAB, A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF TOCILIZUMAB ON DISEASE RESPONSE IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, WITH AN OPEN-LABEL EXTENSION TO EXAMINE THE LONG TERM USE OF TOCILIZUMAB | F. Hoffmann-La Roche AG | $333.34 | 2 |
| A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF TOCILIZUMAB ON DISEASE RESPONSE IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, WITH AN OPEN-LABEL EXTENSION TO EXAMINE THE LONG TERM USE OF TOCILIZUMAB, A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF TOCILIZUMAB ON DISEASE RESPONSE IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, WITH AN OPEN-LABEL EXTENSION TO EXAMINE THE LONG TERM USE OF TOCILIZUMAB, A 24 WEEK RANDOMIZED | F. Hoffmann-La Roche AG | $3.68 | 1 |
About Dr. Hermine Brunner, MD
Dr. Hermine Brunner, MD is a Pediatric Rheumatology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1124011259.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hermine Brunner, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $33,204 received in 2024. These payments were reported across 506 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($947,176).
Ad
Practice Information
- Specialty Pediatric Rheumatology
- Location Cincinnati, OH
- Active Since 08/24/2005
- Last Updated 12/01/2014
- Taxonomy Code 2080P0216X
- Entity Type Individual
- NPI Number 1124011259
Products in Payments
- XELJANZ (Drug) $701,288
- Actemra (Biological) $61,929
- ILARIS (Biological) $32,245
- STELARA (Biological) $31,875
- BENLYSTA (Biological) $23,037
- COSENTYX (Biological) $19,664
- ORENCIA (Biological) $11,640
- Cimzia (Drug) $6,959
- ACZ885M (Biological) $6,401
- SIRUKUMAB (Biological) $2,363
- SIMPONI (Biological) $1,840
- COSENTYX (Drug) $1,744
- OFEV (Drug) $1,455
- SKYRIZI (Biological) $1,300
- TALTZ (Drug) $1,192
- ENBREL (Biological) $994.65
- AIN457F (Biological) $978.75
- AIN457F_COSENTYX_IMMUNOLOGY (Biological) $870.00
- IDACIO (Biological) $360.00
- Humira (Biological) $321.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Rheumatology Doctors in Cincinnati
Daniel Lovell, M.d, M.D
Pediatric Rheumatology — Payments: $264,322
Pediatric Rheumatology $264,322
Alexei Grom, M.d, M.D
Pediatric Rheumatology — Payments: $68,034
Pediatric Rheumatology $68,034
Grant Schulert, M.d, M.D
Pediatric Rheumatology — Payments: $27,455
Pediatric Rheumatology $27,455
Tracy Ting, M.d, M.D
Pediatric Rheumatology — Payments: $10,081
Pediatric Rheumatology $10,081
Esi Morgan, Md, MD
Pediatric Rheumatology — Payments: $5,519
Pediatric Rheumatology $5,519
Jennifer Huggins, Md, MD
Pediatric Rheumatology — Payments: $1,670
Pediatric Rheumatology $1,670